<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418714/" ref="ordinalpos=3674&amp;ncbi_uid=5178919&amp;link_uid=PMC3418714" image-link="/pmc/articles/PMC3418714/figure/F3/" class="imagepopup">Figure 3.  From: The B-cell receptor <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> as a therapeutic target in CLL. </a></div><br /><div class="p4l_captionBody"><b>Kinase inhibitors in CLL.</b> (A) Chemical structures of signal kinase inhibitors. (B) Kinase inhibitors and the BCR pathway.</div></div>